Gain Therapeutics (GANX) News Today $1.92 +0.05 (+2.67%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$1.91 -0.01 (-0.52%) As of 10/20/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 19 at 4:28 AM | marketbeat.comGain Therapeutics price target lowered to $5 from $9 at BTIGOctober 16, 2025 | msn.comBTIG Reiterates Gain Therapeutics (GANX) Buy RecommendationOctober 16, 2025 | msn.comGain Therapeutics to Attend the 2025 Maxim Growth SummitOctober 16, 2025 | globenewswire.comBTIG Research Reiterates "Buy" Rating for Gain Therapeutics (NASDAQ:GANX)October 15, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Gain Therapeutics (NASDAQ:GANX)October 15, 2025 | americanbankingnews.comGain Therapeutics (NASDAQ:GANX) Given "Buy" Rating at HC WainwrightOctober 13, 2025 | marketbeat.comEric Richman Resigns from Gain Therapeutics BoardOctober 10, 2025 | msn.comGain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s DiseaseOctober 9, 2025 | markets.businessinsider.comGain Therapeutics to Host Virtual KOL Event on GT-02287 and Parkinson's Disease ResearchOctober 9, 2025 | quiverquant.comQGain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's DiseaseOctober 9, 2025 | globenewswire.comGain Therapeutics (NASDAQ:GANX) Given Sell (E+) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comGain Therapeutics price target raised to $7 from $5 at MaximOctober 8, 2025 | msn.comGain Therapeutics price target raised to $7 from $5 at MaximOctober 8, 2025 | msn.comGain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim GroupOctober 7, 2025 | marketbeat.comGain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement ...October 6, 2025 | markets.businessinsider.comStock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX)October 6, 2025 | marketbeat.comGain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s DiseaseOctober 6, 2025 | quiverquant.comQGain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®October 6, 2025 | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in SeptemberOctober 6, 2025 | marketbeat.comGain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Buy" from AnalystsSeptember 24, 2025 | marketbeat.comGain Therapeutics to Participate at Drug Discovery Innovation Programme 2025September 23, 2025 | globenewswire.comGain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s DiseaseSeptember 18, 2025 | markets.businessinsider.comGain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’sSeptember 18, 2025 | msn.comGain Therapeutics, Inc. Extends Phase 1b Study of GT-02287 for Parkinson's Disease TreatmentSeptember 18, 2025 | quiverquant.comQGain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's DiseaseSeptember 18, 2025 | globenewswire.comGain Therapeutics' (GANX) Buy Rating Reiterated at BTIG ResearchSeptember 10, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Gain Therapeutics (GANX), Terns Pharmaceuticals (TERN) and Novan (NOVN)September 6, 2025 | theglobeandmail.comGain Therapeutics receives Australian approval of Phase 1b dosing extensionSeptember 4, 2025 | msn.comGain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee RecommendationSeptember 4, 2025 | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 1, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of GANX Q3 EarningsAugust 29, 2025 | marketbeat.comGain Therapeutics Reports Q2 2025 Financial ResultsAugust 21, 2025 | tipranks.comRoth Capital Analysts Increase Earnings Estimates for GANXAugust 17, 2025 | marketbeat.comGain Therapeutics price target lowered to $6 from $7 at Roth CapitalAugust 13, 2025 | msn.comGain Therapeutics reports Q2 EPS (19c), consensus (17c)August 12, 2025 | msn.comGain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comGain Therapeutics (GANX) Projected to Post Earnings on ThursdayAugust 7, 2025 | marketbeat.comGain Therapeutics to Present at BTIG Annual Virtual Biotechnology ConferenceJuly 24, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX), Abbott Laboratories (ABT) and ANI Pharmaceuticals (ANIP)July 19, 2025 | theglobeandmail.comGain Therapeutics Announces Pricing of $7.0 Million Public OfferingJuly 16, 2025 | globenewswire.comGain Therapeutics stock falls after announcing public offeringJuly 16, 2025 | uk.investing.comGain Therapeutics Announces Proposed Public OfferingJuly 15, 2025 | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Buy" by AnalystsJuly 10, 2025 | marketbeat.comGain Therapeutics Inc News (GANX) - Investing.comJuly 8, 2025 | investing.comGain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 MutationJune 30, 2025 | globenewswire.comScotiabank Sticks to Its Buy Rating for Gain Therapeutics (GANX)June 27, 2025 | theglobeandmail.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Buy" by AnalystsJune 15, 2025 | marketbeat.comGain Therapeutics to Participate in Upcoming Investor ConferencesJune 10, 2025 | globenewswire.comGain Therapeutics Announces Oral Presentation at 2nd GBA1 MeetingMay 29, 2025 | globenewswire.com Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GANX Media Mentions By Week GANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GANX News Sentiment▼0.970.50▲Average Medical News Sentiment GANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GANX Articles This Week▼72▲GANX Articles Average Week Get the Latest News and Ratings for GANX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Gain Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SOPHiA GENETICS News Humacyte News Abeona Therapeutics News Allogene Therapeutics News Voyager Therapeutics News Alpha Teknova News Puma Biotechnology News Ventyx Biosciences News Aerovate Therapeutics News Organigram Global News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GANX) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GANX Stock Alerts